He's not a doctor, or an analyst but he tries to play one on the internet.
I have been investing in biotech for 25 years and typically despise and rail against the greedy, ignorant execs that run many biotech firms. It's so refreshing to be invested in a company run by intelligent, shareholder-friendly executives. Congrats and thanks to the EXAS execs for the great job they have done and continue to do for their shareholders. May God Bless them!
I think scripts will get a good bounce after the obesity conference and heading into the new year. We do need some good results in smoking cessation to put a dent in the short thesis at least in the short term.
Good for you Jim. Are you or your group in touch with any BOD members that can get Jack out? I agree, the sooner the better, cash is burning; neither Jack nor his bean counter are right for their job job. And what the heck is ARNA paying Cindy to do in Switzerland?
Business decisions need to be made, cost cutting is needed, capital needs to be allocated properly. We need a turnaround specialist and potentially a sale. I'm not sure anyone would be interested in buying ARNA until they figure out a growth strategy/market for Belviq, or get a new product further along.
Jack has a grip on the Board, we need to loose that grip. Go to work!
well said, the data from the PR was not detailed, more to come next week, more time and likely additional studies to come until this translates into meaningful sales. We really need smoking to work to kill the shorts. Some additional country approvals would also help.
I have been investing in biotech for 25 years. Most of the CEO's are terrible. I am really impressed with the EXAS CEO, he has his act together, he's strong, well prepared, knows how to tell a story, he seems credible and rock solid. I wish my other biotech firms were as well managed at the top. Nice call!
TW has been the only ARNA bull, so I agree, it would be good to know what he is thinking. I suspect that like all of us he is hoping for some good smoking cessation results to bolster the case for his high price target. Maybe he will come down another $1 on the PT. I will take $10 any time in 2015 and be very happy, but not quite retired.
Launching a new product takes time. They have to make MD's and patients aware of the product, companies have to add the product to their list of accepted products. I called Cigna again on Friday and Cologuard is not currently covered by my company plan. I will call the plan admin on Monday and request they add it.
EXAS recently did an offering, so expect some digestion, but the offering was small, so that's not a big factor. Unless the company is acquired, I would expect this type of action to continue. Lower left to upper right is the overall direction, but with corrections of overbought conditions that are mainly caused by the large short position. IMO, not advice.
I sent an em to Craig late last week, no reply yet and he's usually fairly prompt and courteous. Hoping to hear JL is retiring to the BOD soon, but doubt it. Stock is really getting UGLY. Glad I sold some calls, wish I had sold many more. Where is the new IR guy??? I think he's hiding under JL's desk! I am thinking of a joke, but should probably not go there.
Cut and paste from Fiercebiotech today:
Shire is quickly moving on after AbbVie's plot to buy the company for $55 billion fell apart last month, giving the Irish drugmaker a new lease on freedom and a $1.6 billion breakup fee for its trouble. Now CEO Flemming Ornskov, who has presided over 6 acquisitions in his brief tenure, is hinting at more deals to come, pointing to Shire's $4.5 billion deal for ViroPharma last year as a template for the future.
Jack just can't stand to let the share price go over $5 unless he needs to sell some shares and then as soon as they sell, they kill the stock price again. ARNA execs have no credibility and that's why the stock price is low and the inst ownership levels are low. Looks like everyone who failed to sell is a long term investor again. Now the total fully-diluted number of shares is in the 275,000,000 range, but at least they have money to pay Jack's fat salary for another 2 years.
It takes time to roll out a new product. Long term investors should check back in a year. Traders can also make money trading the technicals, but you have to sell high to buy low. Shorts are toast and should admit their mistake and cover ASAP.
I think this is more interesting and exciting than the Roche news and potentially news worthy. As usual, see the IV or IMGN IR board for details and a link. IMGN's scientific teams also received some awards at the ADC conference.
There was no award given for worst CEO.
I suppose we will get an update on the cc, anyone know about the timing other than before year's end? Getting real tired of waiting on this stock to go up.
the stock has been like a narcotic, every once in a while I get a brief transient high, I can't quit and it's ruining my finances.
he should agree to work for $1 until either 1) the stock price gets back to a price above where he bailed or 2) The company becomes stable financially significantly higher revs, significantly lower burn rate, etc. So far, JL has been the major winner while shareholder/owner have suffered.
Chart is improving, technicals suggest the next resting spots (resistance) are 4.77 then 4.95. If it weren't for those pesky shorts, I would say there's a lot of upside potential.